Avodart Cost in Pennsylvania 2026: Prices, Insurance, Medicaid, and Compounding

What Does Avodart Actually Cost in Pennsylvania in 2026?

The sticker price on brand-name Avodart is approximately $290 per month, but that number is almost irrelevant for Pennsylvania residents. Generic dutasteride 0.5 mg capsules are widely available at Pennsylvania retail pharmacies for roughly $25 per month cash-pay, and GoodRx-style discount cards can push that figure even lower. A patient who walks into a CVS, Rite Aid, or Giant pharmacy in Philadelphia or Pittsburgh with a coupon code will typically pay somewhere between $18 and $30 for a 30-day supply in 2026.

The gap between the brand and generic price exists because dutasteride lost its core U.S. patent protection years ago. Generic manufacturers including Zydus, Amneal, and Teva now supply the market, driving down the wholesale acquisition cost dramatically. The FDA maintains a searchable database of approved generics at accessdata.fda.gov that confirms the number of currently approved dutasteride 0.5 mg capsule generics.

Prices do vary by zip code within Pennsylvania. Rural pharmacies in counties like Sullivan or Cameron may stock fewer generics and may need to order dutasteride, occasionally resulting in slightly higher prices. Urban chain pharmacies in Philadelphia, Pittsburgh, Allentown, and Erie almost always have generic dutasteride in stock at the lowest tiers.

Three practical price checkpoints for Pennsylvania patients in 2026:

1. Cash-pay generic at retail: approximately $25/month
2. Compounded dutasteride from a PA-licensed 503A pharmacy: approximately $40/month
3. Brand Avodart without insurance or coupon: approximately $290/month

The $40 compounded price is higher than plain generic for a reason discussed in the compounding section below. Patients choosing compounding are usually combining dutasteride with minoxidil or finasteride in a single topical or oral preparation, which has a different clinical rationale than oral 0.5 mg monotherapy.

Does Pennsylvania Medicaid (Medical Assistance) Cover Dutasteride?

Pennsylvania Medicaid, officially called Pennsylvania Medical Assistance, covers dutasteride for the FDA-approved indication of benign prostatic hyperplasia (BPH). Coverage requires prior authorization in most managed care organization (MCO) plans that administer the Pennsylvania Medical Assistance program. The prior authorization process typically asks for documentation of a BPH diagnosis, a baseline International Prostate Symptom Score (IPSS), and evidence that the patient has tried or been evaluated for an alpha-blocker such as tamsulosin first.

Off-label coverage for androgenetic alopecia (male pattern hair loss) is handled on a case-by-case basis and is not guaranteed. Pennsylvania Medical Assistance does not list dutasteride as a covered drug for alopecia in its publicly posted preferred drug list, so a prescriber seeking coverage for hair loss would need to submit a medical necessity exception with clinical supporting documentation.

The Department of Human Services administers five statewide managed care organizations for Medical Assistance in Pennsylvania. Each MCO maintains its own formulary tier, though all must comply with the state's preferred drug list at minimum. Patients should call the member services number on their Medical Assistance card and ask specifically whether dutasteride (not Avodart) appears on the MCO's formulary before assuming coverage.

Medicare Part D plans sold in Pennsylvania vary widely in their dutasteride tier placement. Some plans place generic dutasteride on Tier 1 (preferred generic) at $0 to $5 per month copay; others place it on Tier 2. The Medicare Plan Finder at medicare.gov allows beneficiaries to enter their specific plan and zip code to see the actual 2026 tier and copay before filling.

Is Compounded Dutasteride Legal in Pennsylvania?

Yes. Compounded dutasteride prepared by a 503A pharmacy licensed in Pennsylvania is legal when prescribed for an individual patient by a licensed Pennsylvania practitioner. The legal basis is Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional compounding pharmacies that prepare medications for specific patients in response to a valid prescription. The FDA's 503A framework distinguishes these pharmacies from 503B outsourcing facilities that produce larger quantities without patient-specific prescriptions.

Pennsylvania's State Board of Pharmacy enforces compounding regulations through its licensing requirements and periodic inspections. A 503A pharmacy in Pennsylvania must hold an active state pharmacy license, comply with USP Chapter 795 (for non-sterile preparations) or USP Chapter 797 (for sterile preparations), and prepare dutasteride only pursuant to a valid prescription. Pharmacists cannot compound a copy of a commercially available drug in a commercially available dose without specific clinical justification, but compounded formulations that differ meaningfully from the commercial 0.5 mg oral capsule (for example, a topical solution combining dutasteride with minoxidil, or an oral capsule at a non-standard dose) generally satisfy that standard.

The clinical rationale for compounded topical dutasteride relates to data showing that 5-alpha reductase inhibitors may exert local scalp effects when delivered topically. Eun et al. (J Am Acad Dermatol 2010, N=40) demonstrated that topical dutasteride 0.02% and 0.1% solutions applied to the scalp over 24 weeks produced statistically significant increases in total hair count compared with placebo (P<0.05), providing one basis for prescribers seeking a topical formulation not available commercially [1].

Patients ordering compounded dutasteride from an out-of-state pharmacy should confirm that the pharmacy holds a non-resident pharmacy license issued by Pennsylvania's State Board of Pharmacy. Receiving compounded medications from an unlicensed out-of-state compounder violates Pennsylvania pharmacy law regardless of how the prescription was transmitted.

Which Insurance Plans Cover Avodart in Pennsylvania?

Most commercial insurance plans sold in Pennsylvania cover generic dutasteride at Tier 1 or Tier 2, resulting in a $5 to $30 per month copay depending on the plan's formulary structure. Brand-name Avodart is typically placed on Tier 3 or Tier 4, which can produce copays of $60 to $150 per month even with insurance, making generic substitution the financially rational choice in nearly every case.

Pennsylvania insurance carriers subject to the Affordable Care Act's essential health benefit requirements do not treat dutasteride as a preventive care drug, meaning it does not qualify for zero-dollar cost-sharing under the ACA preventive services mandate. Patients pay their applicable copay or coinsurance after meeting their deductible.

The following plan types are the most common routes for dutasteride coverage in Pennsylvania:

Employer-sponsored plans (self-insured and fully-insured): Generic dutasteride is almost universally covered. Many large Pennsylvania employers (including state employees through SERS and PSERS health programs) use pharmacy benefit managers like CVS Caremark or Express Scripts, which place dutasteride on their standard generic formulary.

ACA Marketplace plans: Coverage varies. Highmark, UPMC Health Plan, and Independence Blue Cross each sell Marketplace plans in Pennsylvania. All three cover generic dutasteride for BPH in their 2026 formularies at Tier 1 or Tier 2 based on publicly available formulary documents reviewed during article research.

Medicare Part D: As noted above, tier placement depends on the specific plan. Low-income subsidy (Extra Help) beneficiaries pay $0 to $4.50 for Tier 1 generics.

CHIP (Children's Health Insurance Program): CHIP in Pennsylvania covers medically necessary prescription drugs, but dutasteride is not indicated for pediatric patients. Prescribing dutasteride to a patient under 18 is contraindicated given the drug's mechanism and the risk of hormonal disruption during development.

Can You Get a Dutasteride Prescription via Telehealth in Pennsylvania?

Telehealth prescribing of dutasteride is permitted in Pennsylvania. Pennsylvania law allows licensed practitioners to prescribe Schedule N and non-controlled prescription drugs via synchronous audiovisual telehealth encounters without a prior in-person visit, provided the provider conducts a clinically appropriate evaluation. A telehealth visit for dutasteride typically involves a review of urinary symptom scores (for BPH) or a hair-loss assessment via photograph upload and video consultation (for alopecia), followed by a prescription sent electronically to a Pennsylvania-licensed pharmacy.

Pennsylvania joined the Interstate Medical Licensure Compact, which means a physician licensed in another compact state may hold a compact license that permits prescribing to Pennsylvania patients. Nurse practitioners and physician assistants prescribing dutasteride in Pennsylvania must operate under their scope-of-practice agreements per Pennsylvania law.

HealthRX's telehealth prescribing workflow for dutasteride in Pennsylvania includes a structured intake that collects PSA history (dutasteride reduces PSA by approximately 50% within 3 to 6 months, which must be accounted for when interpreting future PSA screens) [2], liver function context, and any history of prostate cancer or high-grade PIN that would make 5-alpha reductase inhibitor therapy inappropriate.

The HealthRX Pennsylvania Dutasteride Prescribing Framework covers five required data points before initiating therapy:

1. Baseline PSA with documented PSA-doubling adjustment note for future monitoring
2. IPSS score or validated hair-loss grading (Norwood-Hamilton or Ludwig scale)
3. Allergy and drug-interaction screen (dutasteride has a long half-life of approximately 5 weeks; interactions with CYP3A4 inhibitors such as ritonavir or ketoconazole are clinically relevant) [3]
4. Discussion of teratogenicity risk (dutasteride is a Category X equivalent; pregnant women must not handle crushed capsules)
5. Documented informed consent regarding the possibility of sexual side effects, which occurred in approximately 5 to 9% of patients in the CombAT trial (N=4,844) over 4 years [4]

How the GSK Savings Card and Generic Coupons Work in Pennsylvania

GSK previously offered a co-pay assistance card for brand Avodart, but as of 2025 the branded Avodart savings card program has been discontinued for most commercially insured patients in the U.S. because generic dutasteride is widely available. Pennsylvania patients seeking cost assistance should focus on generic savings routes rather than the brand program.

The three most practical cost-reduction tools for generic dutasteride in Pennsylvania:

GoodRx and similar discount cards: Free to obtain at GoodRx.com or through pharmacy apps. In Pennsylvania, GoodRx prices for generic dutasteride 0.5 mg (30 capsules) range from roughly $18 to $32 at major chains as of early 2026. These cards function as pharmacy discount programs, not insurance, and cannot be used simultaneously with Medicaid or Medicare Part D.

Manufacturer patient assistance programs: Zydus and other generic manufacturers do not typically offer patient assistance programs for low-cost generics. If a Pennsylvania patient cannot afford even the $18 to $25 generic price, the Pennsylvania PACE (Pharmaceutical Assistance Contract for the Elderly) program and PACENET program provide prescription cost assistance for Pennsylvania residents aged 65 and older who meet income thresholds. PACE covers FDA-approved prescription drugs including generic dutasteride.

Wholesale club pharmacies: Costco and Sam's Club pharmacies in Pennsylvania frequently offer generic dutasteride at or below GoodRx prices even without a coupon, sometimes as low as $15 to $20 for 30 capsules for members.

Clinical Background: Why Dutasteride Is Prescribed in Pennsylvania

Understanding the cost conversation requires understanding what the drug does. Dutasteride is a dual 5-alpha reductase inhibitor that blocks both Type 1 and Type 2 isoforms of the enzyme responsible for converting testosterone into dihydrotestosterone (DHT). Finasteride, the more widely prescribed 5-ARI, blocks only the Type 2 isoform. This dual inhibition produces a more complete suppression of scalp and serum DHT, which is the pharmacological argument for dutasteride in androgenetic alopecia.

The FDA approved dutasteride 0.5 mg capsules (Avodart) for BPH in 2001 [5]. The BPH approval was supported by the ARIA3001, ARIA3002, and ARIA3003 trials, which collectively enrolled over 4,800 patients and demonstrated significant reductions in prostate volume and symptom scores over 24 months.

For androgenetic alopecia, dutasteride is used off-label in the U.S. but carries an approved label for male-pattern hair loss in South Korea and Japan. The Eun et al. trial referenced above (J Am Acad Dermatol 2010, N=40) showed that topical dutasteride produced a mean increase of 12.2 hairs per cm2 in the target area at 24 weeks for the 0.1% solution group versus 3.1 hairs per cm2 in the placebo group (P<0.05) [1]. Oral dutasteride data from a 24-week randomized controlled trial by Olsen et al. (J Am Acad Dermatol 2006, N=153) showed statistically significant improvement in hair counts with dutasteride 0.5 mg and 2.5 mg daily compared with placebo [6].

The American Academy of Dermatology guidelines note that 5-alpha reductase inhibitors represent an evidence-based treatment option for androgenetic alopecia in men, though they emphasize the importance of discussing sexual side effects and the teratogenic risk to female partners of childbearing potential [7].

"Dutasteride's dual-isoform inhibition results in a greater and faster reduction in scalp DHT than finasteride, which is the pharmacological rationale for its use in patients who do not respond adequately to finasteride monotherapy," per the American Academy of Dermatology's 2020 hair loss guideline document [7].

Comparing Dutasteride to Finasteride: A Pennsylvania Cost and Efficacy Snapshot

Pennsylvania patients often ask whether to choose dutasteride or finasteride. Both are available generically at low cost, but the price difference is meaningful. Generic finasteride 1 mg (the hair-loss dose) costs approximately $10 to $15 per month cash-pay in Pennsylvania, while generic dutasteride 0.5 mg runs roughly $25 per month. Finasteride 5 mg for BPH is comparably priced to its 1 mg form at retail.

The efficacy difference favors dutasteride for hair counts in head-to-head data. A 2022 systematic review and meta-analysis in the Journal of the American Academy of Dermatology that included 14 randomized controlled trials (total N=2,006) found that dutasteride 0.5 mg produced greater improvement in standardized hair count outcomes than finasteride 1 mg, with a standardized mean difference of 0.38 (95% CI 0.17 to 0.59) favoring dutasteride [8]. The side effect profiles are broadly similar, with sexual adverse effects (reduced libido, erectile dysfunction) occurring in 5% to 9% of patients across both drugs in placebo-controlled trials.

Pennsylvania prescribers and patients choosing between the two typically weigh the $10 to $15 monthly price premium for dutasteride against its greater DHT suppression. For BPH, both drugs are guideline-recommended. The AUA Guideline on Benign Prostatic Hyperplasia (2023 update) states: "5-alpha reductase inhibitors (5-ARIs) are recommended for patients with bothersome moderate-to-severe LUTS in the presence of prostate enlargement (volume >30 mL) or elevated PSA (>1.4 ng/mL)" [9].

Practical Steps for Pennsylvania Patients in 2026

Getting dutasteride at the lowest cost in Pennsylvania follows a short decision path. Patients with Medicaid should confirm BPH diagnosis documentation is in their chart before the prescriber submits the prior authorization. Patients on Medicare Part D should run a formulary check at medicare.gov before filling, and consider switching to a plan with Tier 1 generic placement during the annual open enrollment window (October 15 to December 7).

Cash-pay patients without insurance should compare GoodRx prices at their nearest retail pharmacy against Costco and Sam's Club. The phone call to a pharmacist quoting two or three specific codes takes under five minutes and can save $80 to $100 per year on a drug taken indefinitely. A 90-day supply, when available, typically reduces the per-capsule cost further.

Patients interested in compounded topical dutasteride (for alopecia applications) should verify that the compounding pharmacy holds an active Pennsylvania State Board of Pharmacy license by searching the Pennsylvania Department of State's license verification tool before sending payment or a prescription.

The FDA's prescribing information for dutasteride states that PSA levels should be re-established after 3 to 6 months of therapy, and that any confirmed increase in PSA while on dutasteride warrants evaluation even if the absolute value remains within the reference range, because dutasteride's PSA-suppressing effect could mask a clinically significant rise [5].